Clinical Trial Update: 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2, single-arm open-label trial of an anti-SLAMF7 monoclonal antibody after autologous stem cell transplant in patients with multiple myeloma has been with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-SLAMF7 monoclonal antibody (anti-SLAMF7 monoclonal antibody)

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN